Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, Kaufmann O, Possinger K
Department of Hematology and Oncology, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Germany.
Ann Hematol. 2001 Oct;80(10):598-601. doi: 10.1007/s002770100361.
There is growing evidence that angiogenesis is important not only in solid tumors but also in hematological malignancies. Recently, we found that bone marrow angiogenesis is a prognostic factor for disease-related survival in patients with multiple myeloma. In this report, we addressed the question of whether the microvessel density in bone marrow biopsies is correlated to other myeloma parameters, e.g., serum beta2-microglobulin (beta2-MG) and plasma cell infiltration in the bone marrow. In 22 multiple myeloma patients, immunohistochemical, CD34-stained, paraffin-embedded bone marrow biopsies before and after chemotherapy were studied. Microvessels were counted in 400x magnification, and the mean number of vessels per area in each sample was noted as the microvessel density (MVD). Pretreatment bone marrow MVD (median: 44, range: 11-175 vessels/mm2) correlated significantly with the bone marrow plasma cell infiltration (median: 30%, range: 5-90%, r = 0.642, P=0.001) and beta2-MG (median: 2.74, range: 1.4-26.1 mg/l, r = 0.749, P < 0.0005). In contrast, there was no correlation between posttreatment MVD and plasma cell infiltration or beta2-MG (median: MVD 31, range: 0-221 vessels/mm2, median plasma cell infiltration: 15%, range: 5-80%, r = 0.229, P = 0.306 and median beta2-MG: 2.65, range: 1-27.6 mg/l, r = -0.042, P = 0.853). These findings show that the strong correlations between bone marrow MVD and plasma cell infiltration as well as serum beta2-MG levels disappear after chemotherapy. The underlying mechanisms need further investigations.
越来越多的证据表明，血管生成不仅在实体瘤中很重要，在血液系统恶性肿瘤中也很重要。最近，我们发现骨髓血管生成是多发性骨髓瘤患者疾病相关生存的一个预后因素。在本报告中，我们探讨了骨髓活检中的微血管密度是否与其他骨髓瘤参数相关，例如血清β2-微球蛋白（β2-MG）和骨髓中的浆细胞浸润。对22例多发性骨髓瘤患者化疗前后的免疫组织化学、CD34染色、石蜡包埋骨髓活检进行了研究。在400倍放大倍数下对微血管进行计数，每个样本每单位面积的血管平均数记为微血管密度（MVD）。化疗前骨髓MVD（中位数：44，范围：11 - 175个血管/mm²）与骨髓浆细胞浸润（中位数：30%，范围：5 - 90%，r = 0.642，P = 0.001）和β2-MG（中位数：2.74，范围：1.4 - 26.1 mg/l，r = 0.749，P < 0.0005）显著相关。相比之下，化疗后MVD与浆细胞浸润或β2-MG之间无相关性（中位数：MVD 31，范围：0 - 221个血管/mm²，中位数浆细胞浸润：15%，范围：5 - 80%，r = 0.229，P = 0.306；中位数β2-MG：2.65，范围：1 - 27.6 mg/l，r = -0.042，P = 0.853）。这些发现表明，化疗后骨髓MVD与浆细胞浸润以及血清β2-MG水平之间的强相关性消失。其潜在机制需要进一步研究。
